Biodiversity Medicine: New Horizon and New Opportunity for Cancer.
Jinghong ChenAbner Herbert LimKhwanta KaewnarinJason Yongsheng ChanCedric Chuan Young NgBin Tean TehPublished in: Cancer discovery (2024)
Accessibility to standard of care remains a challenge to patients in low- and middle-income countries (LMIC), hampering efforts to alleviate the burden of cancer and to improve overall health outcomes. In response to this pressing global health care issue, we propose here a new strategy to create affordable, easily accessible, and effective therapeutic solutions to address this inequity in cancer treatment: the use of science-based biodiversity medicine as an alternative to modern drug therapy, in which we will leverage and combine high-throughput omics technologies with artificial intelligence, to study local biodiversity, their potential anticancer properties, and short- and long-term clinical response and outcomes.
Keyphrases
- artificial intelligence
- healthcare
- papillary thyroid
- high throughput
- end stage renal disease
- machine learning
- big data
- squamous cell
- quality improvement
- ejection fraction
- public health
- chronic kidney disease
- prognostic factors
- palliative care
- emergency department
- stem cells
- pain management
- social media
- young adults
- childhood cancer
- chronic pain
- skeletal muscle
- bone marrow
- human health
- cell therapy
- replacement therapy